Nicox (XPAR:ALCOX) Accounts Payable & Accrued Expense : €2.25 Mil (As of Dec. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Nicox Accounts Payable & Accrued Expense?

Nicox's quarterly accounts payable & accrued expense declined from Dec. 2023 (€3.15 Mil) to Jun. 2024 (€1.58 Mil) but then increased from Jun. 2024 (€1.58 Mil) to Dec. 2024 (€2.25 Mil).

Nicox's annual accounts payable & accrued expense declined from Dec. 2022 (€3.61 Mil) to Dec. 2023 (€3.15 Mil) and declined from Dec. 2023 (€3.15 Mil) to Dec. 2024 (€2.25 Mil).

Nicox Accounts Payable & Accrued Expense Historical Data

The historical data trend for Nicox's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Accounts Payable & Accrued Expense Chart

Nicox Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

2.54

3.82

3.61

3.15

2.25

Nicox Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.61	3.53	3.15	1.58	2.25

Nicox Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Nicox Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

0RCQ:UK NXOA:Germany NXOA:Germany

Address

Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410

Website

https://www.nicox.com

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.

Nicox Headlines

No Headlines